Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) reached a new 52-week high during mid-day trading on Thursday after Oppenheimer raised their price target on the stock from $63.00 to $65.00. Oppenheimer currently has an outperform rating on the stock. Tarsus Pharmaceuticals traded as high as $52.99 and last traded at $49.56, with a volume of 99352 shares traded. The stock had previously closed at $46.51.
Separately, William Blair upgraded shares of Tarsus Pharmaceuticals to a "strong-buy" rating in a report on Friday, August 30th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of "Buy" and an average target price of $52.00.
View Our Latest Report on Tarsus Pharmaceuticals
Institutional Investors Weigh In On Tarsus Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at about $61,000. Canada Pension Plan Investment Board purchased a new stake in Tarsus Pharmaceuticals in the 2nd quarter valued at about $114,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after buying an additional 1,530 shares during the last quarter. FMR LLC increased its stake in shares of Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after purchasing an additional 3,537 shares during the last quarter. Finally, Dark Forest Capital Management LP purchased a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth approximately $202,000. Hedge funds and other institutional investors own 90.01% of the company's stock.
Tarsus Pharmaceuticals Stock Performance
The company's 50 day moving average price is $37.17 and its 200-day moving average price is $32.33. The company has a debt-to-equity ratio of 0.28, a quick ratio of 6.99 and a current ratio of 7.03. The company has a market cap of $1.77 billion, a PE ratio of -11.09 and a beta of 1.00.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Read More
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
